Key Findings From Recent Trials (Research-First Summary)

Basic Zydena Information

• INN (International Nonproprietary Name): Udenafil.
• Brand Names Available In United States: No approvals or branded packaging reported for USA, Canada, or EU as of July 2025.
• ATC Code: G04BE10.
• Forms & Dosages: Tablet 100 mg (4, 8, or 10 tabs) and 200 mg (4 or 8 tabs) in markets such as Korea, CIS, and Asia.
• Manufacturers In United States: Not specified.
• Registration Status In United States: Not approved in the U.S., Canada, or European Union as of July 2025.
• OTC / Rx Classification: Prescription Only (Rx) in all registered countries.

Major 2022–2026 Studies

What recent trials tell clinicians and patients about udenafil.

Published randomized, open-label, and observational reports from 2022–2026 remain limited and are concentrated regionally, especially in South Korea and CIS/Philippines markets.

Most evidence comes from single-country investigator- or industry-initiated trials rather than large multinational randomized controlled trials.

The strongest datasets available are small placebo-controlled or active-comparator trials that use validated endpoints such as the International Index of Erectile Function (IIEF) and erection hardness score, plus pharmacokinetic measurements.

These trials provide short-term efficacy and tolerability data rather than large long-term safety cohorts.

• Primary endpoints reported include IIEF domain improvements and erection hardness metrics.
• Pharmacokinetic studies confirm onset and duration estimates used in labeling.

Main Outcomes

What efficacy signals consistently appear across studies.

Across trials, udenafil has shown consistent improvement in erectile function compared with placebo on short-term endpoints such as IIEF scores.

Onset of effect is typically reported at about 30–60 minutes after oral dosing in study reports and product information.

Effect duration is reported in multiple studies and local labels as lasting up to approximately 12 hours for many patients.

Market-labeled dosing in Korea starts at 100 mg with a maximum single dose of 200 mg per 24 hours for Zydena (Dong-A Pharmaceutical).

Clinical adoption in South Korea and several CIS markets aligns with these efficacy signals.

Safety Observations

Key safety themes follow the PDE5 inhibitor class pattern.

Reported adverse events in trials and postmarketing literature mirror those expected for PDE5 inhibitors, including headache, flushing, nasal congestion, dyspepsia, and back pain.

Transient visual disturbances have been reported but are less frequent than historically described with sildenafil in comparative mentions.

Absolute contraindications emphasized across sources include concurrent nitrate use, severe hepatic or renal impairment, and unstable cardiovascular disease.

Overall tolerability in short-term studies is acceptable and consistent with class effects.

Clinical Mechanism Of Action

Layman’s Explanation

How udenafil helps during sexual activity, explained simply.

Udenafil is a phosphodiesterase type‑5 (PDE5) inhibitor that increases penile blood flow by enhancing nitric oxide–mediated cyclic GMP signaling.

The drug relaxes smooth muscle in the corpus cavernosum during sexual stimulation, which helps achieve and maintain an erection.

Patients are advised to take udenafil 30–60 minutes before anticipated activity, with effect windows reported up to about 12 hours.

Scientific Breakdown

What happens at the molecular level and practical pharmacology notes.

Udenafil selectively inhibits PDE5, reducing cGMP degradation and thereby prolonging vasodilation in penile tissue during sexual stimulation.

Marketed tablet strengths include 100 mg and 200 mg, with labeled on‑demand dosing and a maximum single dose of 200 mg per 24 hours.

Onset and duration are intermediate compared with sildenafil and tadalafil; local pharmacokinetic reports and labels report a moderate onset and up to ~12‑hour duration.

Metabolic clearance is predominantly hepatic, which informs cautions in hepatic impairment and influences dosing decisions.

Pharmacology Implications

How pharmacokinetics guide prescribing choices.

Dosing frequency is limited to one dose per 24 hours and the maximum labeled single dose is 200 mg.

Renal impairment guidance: mild–moderate impairment warrants caution and starting at the lowest feasible dose; severe renal impairment is not recommended due to limited data.

Hepatic impairment guidance: use cautiously in mild liver disease and avoid in moderate to severe hepatic impairment because clinical data are insufficient.

Scope Of Approved And Off-Label Use

United States Approvals

Regulatory reality for clinicians and patients in the U.S.

Zydena (udenafil) is not approved in the United States, Canada, or the European Union as of July 2025.

No U.S. branded packaging or FDA‑labeled indications exist for udenafil, so no FDA dosing guidance is available.

Notable Off-Label Trends

How udenafil is used where it is available and how it appears online.

In licensed markets such as South Korea, Russia/CIS, and the Philippines, udenafil is used on‑label for erectile dysfunction with on‑demand dosing (initial 100 mg, up to 200 mg as labeled).

Some e‑pharmacy listings and small studies report experimental daily low‑dose regimens, but daily use is not widely labeled or approved.

Re‑labeling and alternate packaging names such as Zidena or Udenafilo appear in regional e‑shops and Latin American listings, which raises quality‑control and regulatory concerns.

Clinical Consequences

Advice for prescribers when patients present imported or online-sourced products.

Clinicians in countries where udenafil is not approved should treat prescriptions or patient-supplied product from abroad cautiously because manufacturing, labeling, and pharmacovigilance vary by jurisdiction.

Verify batch numbers and packaging when possible and counsel patients on risks of nonregulated sources.

Dosage Strategy

General Dosing

Practical dosing from the product label used in approved markets.

The labeled regimen for Zydena is an initial 100 mg taken orally 30–60 minutes before sexual activity.

The maximum single dose is 200 mg and dosing should not exceed one dose per 24 hours.

Tablets commonly come as 100 mg (4/8/10 blister packs) and 200 mg (4/8 blister packs) in Korea and CIS markets.

Condition-Specific Dosing

Standard adult dosing and age considerations.

For typical erectile dysfunction in adults, start at 100 mg and titrate to response and tolerability up to 200 mg if needed.

Udenafil is not indicated for individuals under 18 years of age.

Adjustments & Special Populations

How to adjust for elderly patients and organ impairment.

Elderly patients should start at 100 mg and may use the usual adult dose if tolerated.

Mild to moderate renal impairment requires caution and starting at the lowest feasible dose, while severe renal impairment is not recommended.

Use caution in mild hepatic impairment and avoid the drug in moderate to severe hepatic impairment due to insufficient data.

Safety Protocols

Contraindications

Absolute contraindications to watch for before prescribing.

Known hypersensitivity to udenafil or any excipient is an absolute contraindication.

Concurrent use with nitrate medications is absolutely contraindicated because of the risk of severe hypotension.

Severe hepatic or renal impairment and unstable cardiovascular disease (recent myocardial infarction or stroke, unstable angina, severe arrhythmias) are also absolute contraindications.

Adverse Effects

What patients most commonly report after taking udenafil.

Common adverse effects include headache, flushing, nasal congestion, dyspepsia, back pain or myalgia, and dizziness.

Transient visual disturbances have been reported but appear less frequent than with sildenafil in comparative notes.

Priapism and severe hypotension are rare but require urgent evaluation.

Safety Monitoring & Emergency Guidance

Pre‑treatment checks and what to do in emergencies.

Cardiovascular assessment is recommended before initiating any PDE5 inhibitor in patients with cardiac risk factors.

For suspected overdose or priapism, immediate medical attention is required; there is no specific antidote and treatment is symptomatic.

Interaction Mapping

Food Interactions

Does food change how udenafil works?

Udenafil is intended for on‑demand use 30–60 minutes before activity, and high‑fat large meals may delay onset of effect similar to other PDE5 inhibitors.

No specific dietary prohibitions are listed beyond standard PDE5 considerations.

Drug Combinations To Avoid

Key medication interactions that create safety risks.

Concurrent nitrates are an absolute contraindication due to risk of profound hypotension.

Strong CYP3A4 inhibitors or inducers may alter udenafil exposure and should be used with caution; examples in clinical practice include some protease inhibitors, azole antifungals, and certain macrolides where interaction risk is known for drugs primarily cleared hepatically.

Antihypertensive medications can potentiate blood‑pressure lowering effects, so close monitoring is needed if combined.

Practical Checks For Prescribers

A short checklist to reduce interaction risk before prescribing.

• Review the medication list for nitrates and advise absolute avoidance.
• Assess for concurrent alpha‑blocker therapy and plan for low starting doses and BP monitoring if combined.
• Identify potent CYP3A4 inhibitors in the regimen and consider dose adjustments or alternative therapy.

Patient Experience Analysis

Survey Data

What patients report in trials and regional surveys.

Large-scale, multinational patient‑reported outcome data outside Korea and the CIS are limited.

Regional trials and surveys often show meaningful improvement in IIEF scores and patient satisfaction with onset and duration for on‑demand use.

Quality‑of‑life measures in studies vary according to trial design and baseline patient populations.

Forum Trends

Common themes seen in online reviews and e‑pharmacy feedback.

Users on forums and e‑pharmacy review pages frequently praise Zydena for a longer duration of effect—often up to 12 hours—and acceptable tolerability.

Complaints tend to focus on access issues, variable packaging names such as Zidena or Udenafilo, and sourcing concerns when products are bought online.

Reported mild adverse effects such as headache and flushing mirror trial data.

Clinical Implications

How to translate patient sentiment into safer prescribing and counseling.

Expect motivated patients to seek a longer‑lasting PDE5 effect; document baseline cardiac risk and review sourcing if the patient obtained product online.

Confirm product provenance and advise patients to follow labeled dosing and to report any visual changes or syncope immediately.

Distribution And Pricing Landscape

Where Zydena is made, where it’s sold, and what that means for supply and authenticity.

Dong‑A Pharmaceutical in Seoul is the originator and sole manufacturer in Korea for Zydena.

Distribution is concentrated in South Korea, Russia/CIS, the Philippines, and selected Asian markets, with tablets commonly sold in 100 mg and 200 mg blister packs.

Online availability includes licensed e‑pharmacies and secondary market re‑labeled packs such as Zidena or Udenafilo in Latin America and e‑shops.

Public pricing varies widely by market and channel, and some e‑pharmacies offer lower prices but raise authenticity and storage concerns.

Prescription‑only classification in registered countries restricts over‑the‑counter access.

Supply risks include reliance on a single originator manufacturer and the potential for counterfeit or improperly stored products in secondary markets.

In our online pharmacy, zydena is available without a prescription, with discreet delivery to United States in 5-14 days.

Alternative Options

Comparison Table (Narrative)

How udenafil compares with other commonly used PDE5 inhibitors.

All drugs in the PDE5 inhibitor class—sildenafil, tadalafil, vardenafil, avanafil, and udenafil—share overlapping efficacy for erectile dysfunction and similar mechanisms of action.

Udenafil is marketed as having a moderate onset (about 30–60 minutes) and a longer duration (~12 hours) than sildenafil, but a shorter duration than tadalafil, which can extend up to 36 hours.

Side‑effect profiles are broadly similar across the class, and individual tolerability, dosing preferences, and interaction profiles guide agent selection.

Pros And Cons

Simple benefits and limitations to discuss with patients.

Pros: reported longer duration than sildenafil, useful for on‑demand dosing, and long local experience in Korea (approved since 2005).

Cons: limited global regulatory approval (not approved in US/EU/Canada), fewer large multinational randomized trials, and reduced international pharmacovigilance outside Korea and CIS.

When To Consider Alternatives

Choosing between udenafil and better-known PDE5 inhibitors.

Prefer well‑studied agents such as sildenafil or tadalafil when robust local regulatory oversight, insurance coverage, or extensive clinician experience is required.

Consider udenafil where it is available and when the onset/duration profile matches patient goals and local pharmacovigilance is adequate.

Regulatory Status

A current snapshot of approvals and regulatory implications.

As of July 2025, udenafil branded as Zydena by Dong‑A Pharmaceutical is approved and marketed in South Korea since 2005.

The drug is registered and sold in Russia/CIS and the Philippines under brand names such as Zydena and Zidena.

Udenafil is not approved in the United States, Canada, or the European Union as of July 2025.

Classification in registered countries is prescription‑only.

Absence of FDA or EMA approval limits formal clinical guidance from those agencies and reduces the volume of international pharmacovigilance data available to U.S. clinicians.

Re‑labeled or online‑sourced products may bypass regional quality checks, so verifying origin and batch information is important for adverse event reporting.

Consolidated FAQ

Common questions patients ask about Zydena and udenafil.

Is Zydena approved in the US? No—Zydena is not approved in the U.S., Canada, or EU as of July 2025.

How should it be dosed? The labeled starting dose is 100 mg taken 30–60 minutes before activity; do not exceed 200 mg per 24 hours.

What are the major safety concerns? The major concerns are interaction with nitrates, severe hepatic or renal disease, and unstable cardiovascular disease; common side effects include headache, flushing, and nasal congestion.

Can it be used daily? Some small studies and markets report low‑dose daily regimens, but daily use is not widely labeled or approved; on‑demand dosing remains standard.

What packaging and strengths exist? Tablets are available as 100 mg and 200 mg in blister packs; branded Zydena and regional variants such as Zidena or Udenafilo are seen in different markets.

Visual Guide (Content For Imagery & Figures)

Suggested visuals to accompany a professional blog post about udenafil.

1) Mechanism Schematic: a simple flowchart showing NO → cGMP → PDE5 inhibition by udenafil.

2) Dosing Infographic: labeled timeline showing 100 mg initial, 200 mg max, 30–60 minute onset, and up to ~12 hour duration.

3) Market Map: highlight countries with approvals (South Korea, Russia/CIS, Philippines) versus nonapproved regions (US/EU/Canada).

4) Safety Checklist Flowchart: screening for nitrate use, cardiovascular risk, hepatic/renal function, and drug interactions.

5) Packaging Photo Grid: Zydena Korean blister and examples of Zidena/Udenafilo re‑labeling, with captions citing Dong‑A and regulatory notes.

Include accessibility features and clear captions that avoid implying U.S. approval.

Storage And Transport

How to store and what to watch for during transport.

Store zydena tablets below 25°C (77°F) in the original packaging and protect them from moisture and direct sunlight.

Transport should use secure, temperature‑stable, tamper‑evident packaging to preserve tablet integrity.

Blister packs used in Korea and CIS markets reduce direct exposure, but online re‑packaging can compromise authenticity and storage conditions.

Because a single originator manufacturer (Dong‑A Pharmaceutical) produces the drug, reliance on secondary labeling and redistribution increases counterfeit risks.

Advise patients to keep tablets in original blister packs, avoid storing them in humid bathrooms, and discard any product with damaged packaging or expired dates.

Guidelines For Proper Use

Pre-Prescription Assessment

Essential checks before prescribing a PDE5 inhibitor-like udenafil.

Verify erectile dysfunction etiology and perform cardiovascular risk stratification.

Review the full medication list for nitrates and strong CYP3A4 modulators and assess hepatic and renal function.

Explain prescription‑only status and sourcing risks if the patient has imported product from abroad.

Initiation & Titration

How to start and how to adjust dosing safely.

Begin with 100 mg orally 30–60 minutes before sexual activity.

Assess efficacy and tolerability and titrate to 200 mg if needed, without exceeding one dose per 24 hours.

Elderly patients should start at 100 mg and use usual adult dosing if tolerated.

Avoid use in moderate to severe hepatic impairment and use caution in mild to moderate renal impairment.

Counseling Points

What to tell patients at the pharmacy counter or clinic visit.

Expect onset within an hour and possible duration up to about 12 hours for many patients.

Advise common adverse effects such as headache, flushing, nasal congestion, and dyspepsia and instruct patients to seek immediate care for priapism or syncope.

Recommend storage below 25°C in the original blister pack and to report any suspected counterfeit packaging.

Delivery Across United States

Closing Notes For Clinicians And Pharmacists

Practical takeaways when patients ask about zydena or present imported products.

Confirm diagnosis and screen thoroughly for cardiovascular risk and nitrate use before recommending any PDE5 inhibitor.

Verify product origin and packaging when patients provide zydena obtained online or from abroad.

Report adverse events with as much batch and supplier information as possible to local pharmacovigilance authorities.

When local approval and insurance coverage matter, favor well‑studied alternatives such as sildenafil or tadalafil where appropriate and available.

Educate patients about expected onset, duration, dosing limits, common side effects, and storage to support safe and effective use.